{
    "clinical_study": {
        "@rank": "8218", 
        "arm_group": [
            {
                "arm_group_label": "Rotablator", 
                "arm_group_type": "Experimental", 
                "description": "Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.\nRotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.\nConventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
            }, 
            {
                "arm_group_label": "Conventional", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional angioplasty and/or stenting was performed in 120 patients in the C group.\nConventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
            }
        ], 
        "brief_summary": {
            "textblock": "The optimal treatment of calcified coronary lesion remained to be elucidated. A Prospective,\n      randomized controlled trial was perform to explore the immediate effect and long-term\n      outcome of rotational atherectomy in patients with balloon resistant coronary lesion."
        }, 
        "brief_title": "Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The inclusion criteria included patients presenting drug-resistant angina pectoris who\n      underwent balloon resistant angioplasty.\n\n      The exclusion criteria included:\n\n        1. Acute myocardial infarction within the 28 days;\n\n        2. Intolerance to aspirin, clopidogrel, contrast media, or statins;\n\n        3. Angiographic visible thrombus, or dissection;\n\n        4. Left ventricular ejection fraction (LVEF)<35%;\n\n        5. Any type of cancer\n\n        6. Hemorrhagic stroke"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Drug-resistant angina pectoris\n\n          -  Balloon resistant and angiographic calcified coronary lesion\n\n        Exclusion Criteria:\n\n          -  Acute myocardial infarction within 28 days;\n\n          -  Intolerance to aspirin, clopidogrel, contrast media, or statins;\n\n          -  Angiographic visible thrombus, dissection;\n\n          -  LVEF <35%;\n\n          -  Any type of cancer;\n\n          -  Hemorrhagic stroke"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887704", 
            "org_study_id": "ERBRCAL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rotablator", 
                "description": "Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.", 
                "intervention_name": "Rotablator", 
                "intervention_type": "Device", 
                "other_name": "Rotational atherectomy; High-speed rotational atherectomy"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Conventional angioplasty was used in both arms.", 
                "intervention_name": "conventional angioplasty", 
                "intervention_type": "Procedure", 
                "other_name": "percutaneous transluminal coronary angioplasty"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Stenting was implanted in both arms.", 
                "intervention_name": "stenting", 
                "intervention_type": "Procedure", 
                "other_name": "Implantation of coronary stent"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.", 
                "intervention_name": "Cutting balloon", 
                "intervention_type": "Device", 
                "other_name": "Flextome Cutting balloon"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Aspirin will be administrated in participants in both arms.", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug", 
                "other_name": "Bayaspirin, 100mg, tablet, oral, Germany"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Clopidogrel will be administrated to participants in both arms.", 
                "intervention_name": "Clopidogrel", 
                "intervention_type": "Drug", 
                "other_name": "Plavix, Clopidogrel Bisulfate, 100mg, tablet, oral"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Paclitaxel-eluting stent will be used in both arms.", 
                "intervention_name": "Paclitaxel-eluting stent", 
                "intervention_type": "Device", 
                "other_name": "Taxus"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Zotarolimus-eluting stent will be implanted in participants in both arms.", 
                "intervention_name": "zotarolimus-eluting stent", 
                "intervention_type": "Device", 
                "other_name": "Resolute, Medtronic CardioVascular"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Everolimus-eluting stent will be used in both arms.", 
                "intervention_name": "Everolimus-eluting stent", 
                "intervention_type": "Device", 
                "other_name": "Xience V"
            }, 
            {
                "arm_group_label": [
                    "Rotablator", 
                    "Conventional"
                ], 
                "description": "Sirolimus-eluting stent will be used in both arms.", 
                "intervention_name": "Sirolimus-eluting stent", 
                "intervention_type": "Device", 
                "other_name": "Firebird, Shanghai, China"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Clopidogrel", 
                "Sirolimus", 
                "Everolimus", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100029"
                }, 
                "name": "Xinguo Wang"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Rotational Atherectomy on Balloon-resistant Calcified Coronary Lesion the During a Long-term Follow-up Study", 
        "other_outcome": {
            "description": "Procedural complications including death, vessel perforation, dissection, ventricular fibrillation, no reflow, side branch loss. The specific unit of measure will be number of participants with any above mentioned procedural complications.", 
            "measure": "Procedural complications", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed during the process of the procedure, an expected average of 4 hours."
        }, 
        "overall_official": {
            "last_name": "Yujie Zhou, MD.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Follow-up study was performed by experienced doctors through telephone interviews or clinic visits at 1, 3, 6, and 12 months after the procedure, and at every 6 months thereafter. The average duration of follow up was anticipated to be 24 months.", 
            "measure": "Major Adverse Cardiac Events including death, myocardial infarction (MI), target vessel revascularization (TVR) and coronary artery bypass grafting", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for 2 years after the procedure, an expected average of 24 months."
        }, 
        "reference": [
            {
                "PMID": "23351416", 
                "citation": "Chiang MH, Lee WL, Tsao CR, Chang WC, Su CS, Liu TJ, Liang KW, Ting CT. The use and clinical outcomes of rotablation in challenging cases in the drug-eluting stent era. J Chin Med Assoc. 2013 Feb;76(2):71-7. doi: 10.1016/j.jcma.2012.10.004. Epub 2012 Dec 29."
            }, 
            {
                "PMID": "18550555", 
                "citation": "Roy P, Steinberg DH, Sushinsky SJ, Okabe T, Pinto Slottow TL, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Weissman NJ, Lindsay J, Waksman R. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J. 2008 Aug;29(15):1851-7. doi: 10.1093/eurheartj/ehn249. Epub 2008 Jun 11."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887704"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital Medical University", 
            "investigator_full_name": "Yujie Zhou", 
            "investigator_title": "Proffesor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Baseline characteristics were measured on the day of admission to the hospital(baseline).An electrocardiogram was performed 2 h after the procedure. electrocardiograms were required to document any suspicious cardiac ischemic episodes. If any cardiac biomarker elevation was noted after the procedure, further measurements were performed as needed. During their hospital stays, patients were clinically monitored for the occurrence of any adverse events and the need for any additional coronary interventional treatment (In hospital endpoints including death, periprocedural MI).", 
            "measure": "In hospital endpoints including death, periprocedural MI", 
            "safety_issue": "Yes", 
            "time_frame": "In hospital endpoints were doucmented for the duration of hospital stay, an expected average 2 weeks."
        }, 
        "source": "Capital Medical University", 
        "sponsors": {
            "collaborator": {
                "agency": "Beijing Anzhen Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Capital Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}